Andreas Hilpert

Andreas Hilpert, MD, PhD is Professor of Neurology and Head of the Chemotherapy-Induced Neuropathy Research Unit at the University Medical Center Hamburg-Eppendorf. A leading European authority on chemotherapy-induced peripheral neuropathy (CIPN), Professor Hilpert has led multicenter trials evaluating preventive strategies for taxane- and platinum-induced neuropathy, and has developed standardized electrophysiological and patient-reported outcome assessment protocols that are used in investigational neurotoxicity studies across Germany, Austria, and Switzerland. He contributed to the validation of the European Organisation for Research and Treatment of Cancer (EORTC) CIPN-20 questionnaire and has published seminal mechanistic studies on the pathophysiology of oxaliplatin-induced neuropathy, including cold allodynia and chronic sensory loss. His research on duloxetine as a treatment for established CIPN, informed by ALLIANCE A221201 trial data, has contributed to current ASCO guideline recommendations. Professor Hilpert is an active member of the MASCC Neurological Complications study group.